Cargando…
Efficacy matters: broadening complement inhibition in COVID-19
Autores principales: | Mastellos, Dimitrios C, Skendros, Panagiotis, Calado, Rodrigo T, Risitano, Antonio M, Lambris, John D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836746/ https://www.ncbi.nlm.nih.gov/pubmed/33521674 http://dx.doi.org/10.1016/S2665-9913(20)30423-9 |
Ejemplares similares
-
Efficacy matters: broadening complement inhibition in COVID-19 – Authors' reply
por: Vlaar, Alexander P J, et al.
Publicado: (2021) -
Complement as a target in COVID-19?
por: Risitano, Antonio M., et al.
Publicado: (2020) -
Response to “Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19”
por: Mastellos, Dimitrios C., et al.
Publicado: (2021) -
Author Correction: Complement as a target in COVID-19?
por: Risitano, Antonio M., et al.
Publicado: (2020) -
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy
por: Mastellos, Dimitrios C., et al.
Publicado: (2020)